Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track ...
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP609 (idursulfase-IT; also known as HGT-2310) for the treatment of neurocognitive decline associated ...
FierceDrugDelivery - Sun, 25 Jan 2015 22:56



GSK expands its portfolio of medicines in the US for patients with asthma and ...
These are the third and fourth respiratory products we've introduced since October 2013 in our patented Ellipta inhaler," said Jorge Bartolome, Senior Vice President of the GSK Respiratory Business Unit in the US. "The Ellipta allows for a common ...
SYS-CON Media (press release) - Mon, 26 Jan 2015 06:15

BioDelivery Sciences International Inc.: BioDelivery Sciences Acquires North ...
Meda has over the past few years decided to primarily focus on the respiratory area in the U.S., which led to the present agreement that provides BDSI with an opportunity to seek one or more new commercial partners for ONSOLIS. BDSI will have the right ...
The Wall Street Transcript - Tue, 27 Jan 2015 04:00



Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now ...
... respiratory depression, acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment, known or suspected paralytic ileus and gastrointestinal obstruction, and hypersensitivity to any component of Hysingla ...
SYS-CON Media (press release) - Mon, 26 Jan 2015 06:26

$6.6M. Haverhill Police Station Fraud – Unhealthy Work Conditions
According to the EPA: Research studies have shown that exposures to building dampness and mold have been associated with respiratory symptoms, asthma, hypersensitivity pneumonitis, rhino sinusitis, bronchitis, and respiratory infections. Individuals ...
The Valley Patriot - Thu, 22 Jan 2015 08:30

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and ...
NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with ...
PR Newswire (press release) - Tue, 20 Jan 2015 10:22

Novartis announces FDA approval for first IL-17A antagonist Cosentyx ...
EAST HANOVER, N.J., Jan. 21, 2015 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) has approved Cosentyx™ (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are ...
MarketWatch - Wed, 21 Jan 2015 10:22

Hysingla ER by Purdue Pharma LP
Hysingla ER is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected paralytic ileus and gastrointestinal obstruction, or hypersensitivity to the active ingredient or any other ...
Pharmacy Times - Mon, 12 Jan 2015 08:53


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014